On September 29, 2025 TAE Life Sciences (TLS) reported preclinical results from its collaboration with Kyoto University, demonstrating that its next-generation boron drugs, when combined with immune checkpoint inhibitors, significantly inhibited tumor growth in certain conditions compared with either immunotherapy alone or BNCT alone (Press release, TAE Life Sciences, SEP 29, 2025, View Source [SID1234656331]). Based on the ongoing success of this collaboration and the exciting data being generated, TLS and Kyoto University have extended their BNCT research partnership through December 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TLS’s findings are consistent with recent third-party publications highlighting the unique synergy between BNCT and checkpoint inhibitors. Both independent 2024 studies from Japan reported that combining BNCT with PD-1/PD-L1 blockade enhanced tumor control and survival, reinforcing TLS’s own observations of synergistic immune activation. This alignment underscores the translational potential of TLS’s BNCT-immunotherapy strategy.
"These preclinical results with TLS proprietary boronated compounds confirm the potential to not only deliver targeted BNCT but also amplify the effects of immunotherapy," said Rob Hill, CEO of TAE Life Sciences. "This in turn expands our clinical opportunity and strengthens our position in both oncology and the fast-growing immunotherapy markets."
"Our partnership with Kyoto University has been critical in driving novel drug development for BNCT," added Kendall Morrison, Chief Scientific Officer at TLS. "By extending this partnership through 2026, we ensure continuity in preclinical testing, combination optimization, and translational research that supports our IND-enabling path."
Strategic outlook
These results reinforce the potential for TLS’s novel boronated drugs to transform BNCT from a targeted radiation therapy into a powerful immuno-oncology strategy. By combining the precision of BNCT with the systemic effects of checkpoint inhibition, these drugs may help overcome resistance, broaden patient benefit, and establish a new standard for difficult-to-treat cancers. The extension of TLS’s partnership with Kyoto University provides a strong foundation to advance this program toward IND-enabling studies, first-in-human trials and upcoming scientific milestones.